Haemophilus influenzae Type B Infections - Pipeline

Review, H2 2015 Is Released

Haemophilus influenzae Type B Infections - Pipeline Review, H2 2015 Summary Global Markets Direct s,
Haemophilus influenzae Type B Infections - Pipeline Review, H2 2015 , provides an overview of the
Haemophilus influenzae Type B Infections s therapeutic pipeline. This report provides comprehensive
information on the therapeutic development for Haemophilus influenzae Type B Infections, complete
with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured
news and press releases. It also reviews key players involved in the therapeutic development for
Haemophilus influenzae Type B Infections and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy
areas and nearly 3,000 indications. The report is built using data and information sourced from Global
Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations
and featured press releases from company/university sites and industry-specific third party sources, put
together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes
periodic updation following a stringent set of processes that ensures that all the profiles are updated
with the latest set of information. Additionally, processes including live news & deals tracking, browser
based alert-box and clinical trials registries tracking ensure that the most recent developments are
captured on a real time basis. The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying
new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the
report may be removed or altered based on the availability and relevance of data for the indicated
disease. Scope - The report provides a snapshot of the global therapeutic landscape of Haemophilus
influenzae Type B Infections - The report reviews key pipeline products under drug profile section which
includes, product description, MoA and R&D brief, licensing and collaboration details & other
developmental activities - The report reviews key players involved in the therapeutics development for
Haemophilus influenzae Type B Infections and enlists all their major and minor projects - The report
summarizes all the dormant and discontinued pipeline projects - A review of the Haemophilus
influenzae Type B Infections products under development by companies and universities/research
institutes based on information derived from company and industry-specific sources - Pipeline products
coverage based on various stages of development ranging from pre-registration till discovery and
undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Haemophilus influenzae Type B Infections pipeline on the basis of target, MoA, route of
administration and molecule type - Latest news and deals relating related to pipeline products Reasons
to buy - Provides strategically significant competitor information, analysis, and insights to formulate
effective R&D development strategies - Identify emerging players with potentially strong product
portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic
initiatives by understanding the focus areas of leading companies - Identify and understand important
and diverse types of therapeutics under development for Haemophilus influenzae Type B Infections Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Haemophilus influenzae Type B
Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out1

licensing strategies by identifying prospective partners with the most attractive projects to enhance and
expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove them from pipeline.
with
TOC
@
http://www.idatainsights.com/reports-landingpage.php?id=173376/haemophilus-influenzae-type-b-infections-pipeline-review-h2-2015

Browse

To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173376/haemophilus-influenzae-type-b-infections-pipeline-review-h2-2015

Table of Contents

Introduction 7
Global Markets Direct Report Coverage 7
Haemophilus influenzae Type B Infections Overview 8
Therapeutics Development 9
Pipeline Products for Haemophilus influenzae Type B Infections - Overview 9
Pipeline Products for Haemophilus influenzae Type B Infections - Comparative Analysis 10
Haemophilus influenzae Type B Infections - Therapeutics under Development by Companies 11
Haemophilus influenzae Type B Infections - Therapeutics under Investigation by Universities/Institutes
12
Haemophilus influenzae Type B Infections - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Haemophilus influenzae Type B Infections - Products under Development by Companies 16
Haemophilus influenzae Type B Infections - Products under Investigation by Universities/Institutes 17
Haemophilus influenzae Type B Infections - Companies Involved in Therapeutics Development 18
Beijing Minhai Biotechnology Co., Ltd 18
Biological E. Limited 19
CSL Limited 20
Daiichi Sankyo Company, Limited 21
2

Indian Immunologicals Limited 22

LG Life Science LTD. 23
Nuron Biotech, Inc. (Inactive) 24
Panacea Biotec Limited 25
Sanofi Pasteur SA 26
Sinovac Biotech Ltd. 27
Zydus Cadila Healthcare Limited 28
Haemophilus influenzae Type B Infections - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Target 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
(diphtheria + pertussis (wholl cell) + tetanus + hepatitis B + Haemophilus influenza [serotype B])
(pentavalent) vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
(diphtheria + tetanus + pertussis (acellular) + Haemophilus influenza [serotype B] + polio) vaccine - Drug
Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
(diphtheria + tetanus + pertussis (acellular) + Haemophilus influenza [serotype B]) vaccine - Drug Profile
39
Product Description 39
Mechanism of Action 39

R&D Progress 39
(diphtheria + tetanus + pertussis (whole cell) + Haemophilus influenzae [serotype B] + polio)
(pentavalent) vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + poliomyelitis + Haemophilus influenzae
[serotype B]) (hexavalent) vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
(diphtheria + tetanus + pertussis (whole-cell) + Haemophilus influenzae [serotype B]) vaccine - Drug
Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
(diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + Haemophilus influenzae [serotype B])
(pentavalent) vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
(diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + Haemophilus influenzae [serotype B])
vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
(diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + Haemophilus influenzae [serotype B] +
hepatitis B + meningococcal [serotype C]) (7-valent) vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
4

R&D Progress 45
(diphtheria + tetanus+ pertussis (whole cell) + hepatitis B + Haemophilus influenzae [serotype B])
(pentavalent) vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
haemophilus influenza [serotype B] vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
haemophilus influenzae [serotype B] vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
haemophilus influenzae [serotype B] vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
haemophilus influenzae [serotype B] vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
haemophilus influenzae [serotype B] vaccine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
NU-300 - Drug Profile 52
5

Product Description 52
Mechanism of Action 52
R&D Progress 52
PR-5I - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
VN-0105 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Haemophilus influenzae Type B Infections - Recent Pipeline Updates 56
Haemophilus influenzae Type B Infections - Dormant Projects 58
Haemophilus influenzae Type B Infections - Product Development Milestones 59
Featured News & Press Releases 59
Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur s
Investigational Pediatric Hexavalent Vaccine 59
Sep 26, 2013: Takeda Submits New Drug Application in Japan for TAK-816, a Haemophilus Influenzae
type b vaccine 60
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62

Read More
http://www.idatainsights.com/reports-landing-page.php?id=173376/haemophilusinfluenzae-type-b-infections-pipeline-review-h2-2015
About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading
market research information aggregator and marketing research consulting firm. We conduct both
primary and secondary research. Our work does not end with research it is also involved in distributing
reports for different companies . We provide actionable recommendations and provide our expertise for
business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and
discovery, and then be their guide in the implementation of changes that will make a difference to their
bottom line.
ContactUs:
iData Insights
Tel: 1-866-237-2965
Web: http://www.idatainsights.com
Email: info@idatainsights.com
About iData Insights
We work around the clock until our clients are completely satisfied with their promised results. It is our
mission to provide timely services coupled with acute client care to create a long-lasting relationship
with you. We deliver on our promise to provide results that are essential to the success of your
company. We believe that by doing so, we will earn the trust of our clients for future projects